Resistance to anti-HCV protease inhibitors

Current Opinion in Virology

Volumn 1, Issue 6, 2011, Pages 599-606

  Thompson, Alexander J ^a,b   Locarnini, Stephen A ^b   Beard, Michael R ^c  

^a ST VINCENT S HOSPITAL   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 450; ASUNAPREVIR; BI 201335; BMS 790052; BMS 791325; BOCEPREVIR; CILUPREVIR; DANOPREVIR; GS 9256; MERICITABINE; MK 5172; NARLAPREVIR; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TEGOBUVIR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; VANIPREVIR; VIRUS RNA; VX 222;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 82955162670     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.10.001     Document Type: Review

References (55)

1. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl. 1 2009 74 81
2. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, and R. Flisiak Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
3. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G.R. Foster, and A. Horban Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
4. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, and N. Boparai Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
5. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, S. Zeuzem, F. Poordad, Z.D. Goodman, H.L. Sings, and N. Boparai Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
6. R. Bartenschlager, and V. Lohmann Replication of hepatitis C virus J Gen Virol 81 Pt 7 2000 1631 1648 (Pubitemid 30427068)
7. J. Bukh, R.H. Miller, and R.H. Purcell Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes Semin Liver Dis 15 1995 41 63
8. S. Duffy, L.A. Shackelton, and E.C. Holmes Rates of evolutionary change in viruses: patterns and determinants Nat Rev Genet 9 2008 267 276 (Pubitemid 351399833)
9. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra2
10. C.L. Tai, W.K. Chi, D.S. Chen, and L.H. Hwang The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3) J Virol 70 1996 8477 8484
11. R. Thimme, V. Lohmann, and F. Weber A target on the move: innate and adaptive immune escape strategies of hepatitis C virus Antiviral Res 69 2006 129 141 (Pubitemid 43247333)
12. K. Li, E. Foy, J.C. Ferreon, M. Nakamura, A.C. Ferreon, M. Ikeda, S.C. Ray, M. Gale Jr., and S.M. Lemon Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF Proc Natl Acad Sci USA 102 2005 2992 2997 (Pubitemid 40299904)
13. E. Meylan, J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, and J. Tschopp Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus Nature 437 2005 1167 1172 (Pubitemid 41509355)
14. E. Foy, K. Li, R. Sumpter Jr., Y.M. Loo, C.L. Johnson, C. Wang, P.M. Fish, M. Yoneyama, T. Fujita, S.M. Lemon, and M. Gale Jr. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling Proc Natl Acad Sci USA 102 2005 2986 2991 (Pubitemid 40299903)
15. N. Yao, P. Reichert, S.S. Taremi, W.W. Prosise, and P.C. Weber Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase Structure 7 1999 1353 1363 (Pubitemid 29529876)
16. J.L. Kim, K.A. Morgenstern, C. Lin, T. Fox, M.D. Dwyer, J.A. Landro, S.P. Chambers, W. Markland, C.A. Lepre, and E.T. O'Malley Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide Cell 87 1996 343 355 (Pubitemid 26359011)
17. N. Yao, T. Hesson, M. Cable, Z. Hong, A.D. Kwong, H.V. Le, and P.C. Weber Structure of the hepatitis C virus RNA helicase domain Nat Struct Biol 4 1997 463 467 (Pubitemid 27263599)
18. H.S. Cho, N.C. Ha, L.W. Kang, K.M. Chung, S.H. Back, S.K. Jang, and B.H. Oh Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA J Biol Chem 273 1998 15045 15052 (Pubitemid 28272799)
19. J.L. Kim, K.A. Morgenstern, J.P. Griffith, M.D. Dwyer, J.A. Thomson, M.A. Murcko, C. Lin, and P.R. Caron Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding Structure 6 1998 89 100 (Pubitemid 28084402)
20. S.L. Uprichard Hepatitis C virus experimental model systems and antiviral drug research Virol Sin 25 2010 227 245
21. K. Lin, R.B. Perni, A.D. Kwong, and C. Lin VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells Antimicrob Agents Chemother 50 2006 1813 1822
22. Phenotypic characterization of telaprevir (VX-950) protease variants in a HCV replicon system Y. Zhou, D. Bartels, and U. Muh 13th International Symposium on Hepatitis C Virus and Related Viruses Cairns, Australia 2006
23. X. Tong, R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B.A. Malcolm Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral Res 70 2006 28 38
24. X. Qi, A. Bae, S. Liu, H. Yang, S.C. Sun, J. Harris, W. Delaney, M. Miller, and H. Mo Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates Antiviral Res 81 2009 166 173
25. J. Binder, S. Tetangco, M. Weinshank, K. Maegley, L. Lingardo, W. Diehl, R. Love, A.K. Patick, and G.J. Smith 3rd. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors Antiviral Res 91 2011 102 111
26. J.M. Gottwein, T.K. Scheel, T.B. Jensen, L. Ghanem, and J. Bukh Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses Gastroenterology 141 2011 1067 1079
27. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H.M. Chu, and C. Lin Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
28. T.L. Kieffer, C. Sarrazin, J.S. Miller, M.W. Welker, N. Forestier, H.W. Reesink, A.D. Kwong, and S. Zeuzem Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639 (Pubitemid 47436107)
29. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
30. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
31. N. Forestier, H.W. Reesink, C.J. Weegink, L. McNair, T.L. Kieffer, H.M. Chu, S. Purdy, P.L. Jansen, and S. Zeuzem Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C Hepatology 46 2007 640 648 (Pubitemid 47436108)
32. Merck: FDA Antiviral Drugs Advisory Committee Meeting: boceprevir capsules (NDA 202-258) briefing document. Published March 29 AahwfgdAC.
33. US Department of Health & Human Services: Advisory committee briefing document for NDA 201-917 telaprevir 375 mg tablets. Published April 1 Aahwf.
34. S. Chevaliez, C. Rodriguez, A. Soulier, A. Ahmed-Belkacem, C. Hézode, and J.M. Pawlotsky Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: pre-existing resistant variants and dynamics of resistant populations J Hepatol 54 Suppl. 1 2011 S30 (A67)
35. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J.P. Bronowicki, M. Bourliere, S. Gharakhanian, and L. Bengtsson Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
36. S. Zeuzem, F. Poordad, S.C. Gordon, I.M. acobson, R. Ralston, V. Sniukiene, J.A. Howe, R.A. Ogert, N. Boparai, and C.A. Brass Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin J Hepatol 54 Suppl. 1 2011 Abstract 8
37. S. Zeuzem, R.J. Barnard, J.A. Howe, R.A. Ogert, R. Ralston, N. Bopari, C.A. Brass, J.K. Albrecht, M. Burroughs, and V. Sniukiene Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials J Hepatol 54 Suppl. 1 2011 S4 (A9)
38. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, and A.J. Muir Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
39. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, and E. Powell IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
40. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, and S. Hige Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
41. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, K.V. Shianna, T. Urban, N.H. Afdhal, I.M. Jacobson, and R. Esteban Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120-129 e18
42. F. Poordad, J.P. Bronowicki, S. Gordon, S. Zeuzem, I. Jacobson, M. Sulkowski, T. Poynard, T.R. Morgan, M. Burroughs, and V. Sniukiene IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) Combination Ther J Hepatol 54 2011 S6
43. I.M. Jacobson, I. Catlett, P. Marcellin, N.H. Bzowej, A.J. Muir, N. Adda, L. Bengtsson, S. George, S. Seepersaud, and R. Ramachandran Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial J Hepatol 54 Suppl. 1 2011 S542 (A1369)
44. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252343.pdf, 2. UpAA.
45. E.J. Gane, S.K. Roberts, C.A. Stedman, P.W. Angus, B. Ritchie, R. Elston, D. Ipe, P.N. Morcos, L. Baher, and I. Najera Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
46. A.M. Di Bisceglie, D.R. Nelson, E. Gane, K. Alves, M.L. Koziel, C. De Souza, T.L. Kieffer, S. George, R.S. Kauffman, and I.M. Jacobson VX-222 with TVR alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic Hepatitis C: zenith study interim results J Hepatol 54 Suppl. 1 2011 S540 (A1363)
47. S. Zeuzem, P. Buggisch, and K. Agarwal Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment-naive, genotype 1 HCV subjects Hepatology 52 Suppl. 1 2010 LB1 (abs)
48. A.S. Lok, D.F. Gardiner, and E. Lawitz Combined therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotyoe 1 null responders Hepatology 52 Suppl. 1 2010 LB-8 (abs)
49. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G. Everson, R. Ghalib, R. Reindollar, V. Rustgi, P. Wendelburg, and K. Zhu Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders J Hepatol 54 2011 A1356
50. Y. He, M.S. King, D.J. Kempf, L. Lu, H.B. Lim, P. Krishnan, W. Kati, T. Middleton, and A. Molla Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system Antimicrob Agents Chemother 52 2008 1101 1110 (Pubitemid 351358394)
51. M.F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors Antimicrob Agents Chemother 52 2008 1604 1612 (Pubitemid 351614649)
52. S.W. Ludmerer, D.J. Graham, E. Boots, E.M. Murray, A. Simcoe, E.J. Markel, J.A. Grobler, O.A. Flores, D.B. Olsen, D.J. Hazuda, and R.L. LaFemina Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay Antimicrob Agents Chemother 49 2005 2059 2069 (Pubitemid 40631625)
53. S. Le Pogam, H. Kang, S.F. Harris, V. Leveque, A.M. Giannetti, S. Ali, W.R. Jiang, S. Rajyaguru, G. Tavares, and C. Oshiro Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus J Virol 80 2006 6146 6154 (Pubitemid 43849192)
54. H. Mo, L. Lu, T. Pilot-Matias, R. Pithawalla, R. Mondal, S. Masse, T. Dekhtyar, T. Ng, G. Koev, and V. Stoll Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro Antimicrob Agents Chemother 49 2005 4305 4314 (Pubitemid 41400978)
55. Y. Zhou, D.J. Bartels, B.L. Hanzelka, U. Muh, Y. Wei, H.M. Chu, A.M. Tigges, D.L. Brennan, B.G. Rao, and L. Swenson Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 52 2008 110 120